

---

**PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FINANCIAL RESULTS  
FOR THIRD QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2019**

---

The Board of Directors (the “**Board**”) of Pharmesis International Ltd. (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) wishes to announce that after preliminary assessment of the Group’s unaudited financial results for the third quarter (“**3QFY2019**”) and nine months ended 30 September 2019 (“**9MFY2019**”), the Board would like to advise that the Group is expected to report a net loss for 3QFY2019 and 9MFY2019.

The expected net loss was mainly attributed to lower sales during the 3QFY2019 and 9MFY2019.

Further details of the Group’s financial performance will be disclosed when the Company announces its unaudited financial results for 3QFY2019 and 9MFY2019.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

**BY ORDER OF THE BOARD**

Wu Xuedan  
Executive Director and Chief Executive Officer  
4 November 2019